{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:55Z","timestamp":1773878455988,"version":"3.50.1"},"reference-count":12,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"4","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1002\/cac2.12661","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T05:55:26Z","timestamp":1737006926000},"page":"471-475","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives"],"prefix":"10.34133","volume":"45","author":[{"given":"Ruben","family":"Malmberg","sequence":"first","affiliation":[{"name":"University Medical Center","place":["Rotterdam, The Netherlands"]},{"name":"Erasmus University Medical Center","place":["Rotterdam, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1825-2911","authenticated-orcid":false,"given":"Bram C.","family":"Agema","sequence":"additional","affiliation":[{"name":"University Medical Center","place":["Rotterdam, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maaike M.","family":"Hofman","sequence":"additional","affiliation":[{"name":"University Medical Center","place":["Rotterdam, The Netherlands"]},{"name":"University Medical Center","place":["Rotterdam, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7488-2002","authenticated-orcid":false,"given":"Stefani","family":"Oosterveld","sequence":"additional","affiliation":[{"name":"Erasmus University Medical Center","place":["Rotterdam, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander","family":"Bins","sequence":"additional","affiliation":[{"name":"University Medical Center","place":["Rotterdam, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne W.","family":"Dumoulin","sequence":"additional","affiliation":[{"name":"University Medical Center","place":["Rotterdam, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjen","family":"Joosse","sequence":"additional","affiliation":[{"name":"University Medical Center","place":["Rotterdam, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim G. J. V.","family":"Aerts","sequence":"additional","affiliation":[{"name":"University Medical Center","place":["Rotterdam, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reno","family":"Debets","sequence":"additional","affiliation":[{"name":"University Medical Center","place":["Rotterdam, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit C. P.","family":"Koch","sequence":"additional","affiliation":[{"name":"Erasmus University Medical Center","place":["Rotterdam, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid A. M.","family":"van der Veldt","sequence":"additional","affiliation":[{"name":"University Medical Center","place":["Rotterdam, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roelof W. F.","family":"van Leeuwen","sequence":"additional","affiliation":[{"name":"University Medical Center","place":["Rotterdam, The Netherlands"]},{"name":"Erasmus University Medical Center","place":["Rotterdam, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-5697","authenticated-orcid":false,"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[{"name":"University Medical Center","place":["Rotterdam, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"221","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"issue":"12","key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/S1470-2045(22)00554-X","article-title":"Alternative dosing strategies for immune checkpoint inhibitors to improve cost\u2010effectiveness: a special focus on nivolumab and pembrolizumab","volume":"23","author":"Malmberg R","year":"2022","unstructured":"Malmberg R, Zietse M, Dumoulin DW, Hendrikx J, Aerts J, van der Veldt AAM, et\u00a0al. Alternative dosing strategies for immune checkpoint inhibitors to improve cost\u2010effectiveness: a special focus on nivolumab and pembrolizumab. Lancet Oncol. 2022;23((12)):e552\u2013e61.","journal-title":"Lancet Oncol"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107950","article-title":"Real\u2010world overall survival after alternative dosing for pembrolizumab in the treatment of non\u2010small cell lung cancer: A nationwide retrospective cohort study with a non\u2010inferiority primary objective","volume":"196","author":"Grit GF","year":"2024","unstructured":"Grit GF, van Geffen E, Malmberg R, van Leeuwen R, B\u00f6hringer S, Jm Smit H, et\u00a0al. Real\u2010world overall survival after alternative dosing for pembrolizumab in the treatment of non\u2010small cell lung cancer: A nationwide retrospective cohort study with a non\u2010inferiority primary objective. Lung Cancer. 2024;196:107950.","journal-title":"Lung Cancer"},{"issue":"11","key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/oncolo\/oyad182","article-title":"Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non\u2010Small Cell Lung Cancer","volume":"28","author":"Dub\u00e9\u2010Pelletier M","year":"2023","unstructured":"Dub\u00e9\u2010Pelletier M, Labb\u00e9 C, C\u00f4t\u00e9 J, Pelletier\u2010St\u2010Pierre AA. Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non\u2010Small Cell Lung Cancer. Oncologist. 2023;28((11)):969\u201377.","journal-title":"Oncologist"},{"key":"e_1_3_2_5_2","unstructured":"Pharmacokinetic\u2010Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor\u20101 (PD\u20101) or Programmed Cell Death\u2010Ligand 1 (PD\u2010L1) Blocking Antibodies for Treatment of Patients with Cancer Guidance for Industry: U.S. Department of Health and Human Services Food and Drug Administration Oncology Center of Excellence (OCE) Center for Drug Evaluation and Research (CDER); 2022 [cited 2024 January 30th]. Available from: https:\/\/www.fda.gov\/media\/151745\/download"},{"key":"e_1_3_2_6_2","unstructured":"Review Memo: Supplemental Biologics License Application for Pembrolizumab 400 mg every six weeks: US Food and Drug Administration; 2020 [updated April 13th; cited 2021 December 13th]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125514s59\u201064 69 76\u201083SumR.pdf"},{"issue":"1","key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/cpt.2170","article-title":"Pivotal Dose of Pembrolizumab: A Dose\u2010Finding Strategy for Immuno\u2010Oncology","volume":"110","author":"Li TR","year":"2021","unstructured":"Li TR, Chatterjee M, Lala M, Abraham AK, Freshwater T, Jain L, et\u00a0al. Pivotal Dose of Pembrolizumab: A Dose\u2010Finding Strategy for Immuno\u2010Oncology. Clin Pharmacol Ther. 2021;110((1)):200\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_3_2_8_2","unstructured":"Assessment report Keytruda Procedure No. EMEA\/H\/C\/003820\/II\/0065: European Medicines Agency; 2019 [cited 2022 February 24th]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/variation\u2010report\/keytruda\u2010h\u2010c\u20103820\u2010ii\u20100065\u2010epar\u2010assessment\u2010report\u2010variation_en.pdf"},{"issue":"23","key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","article-title":"Pembrolizumab Exposure\u2013Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance","volume":"24","author":"Turner DC","year":"2018","unstructured":"Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, et\u00a0al. Pembrolizumab Exposure\u2013Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clin Cancer Res. 2018;24((23)):5841\u20139.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejca.2020.02.016","article-title":"A six\u2010weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation","volume":"131","author":"Lala M","year":"2020","unstructured":"Lala M, Li TR, de Alwis DP, Sinha V, Mayawala K, Yamamoto N, et\u00a0al. A six\u2010weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur J Cancer. 2020;131:68\u201375.","journal-title":"Eur J Cancer"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15497"},{"issue":"10","key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1016\/S1470-2045(24)00218-3","article-title":"The tyranny of non\u2010inferiority trials","volume":"25","author":"Tannock IF","year":"2024","unstructured":"Tannock IF, Buyse M, De Backer M, Earl H, Goldstein DA, Ratain MJ, et\u00a0al. The tyranny of non\u2010inferiority trials. Lancet Oncol. 2024;25((10)):e520\u2013e5.","journal-title":"Lancet Oncol"},{"issue":"5","key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10928-017-9528-y","article-title":"Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response","volume":"44","author":"Li H","year":"2017","unstructured":"Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, et\u00a0al. Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn. 2017;44((5)):403\u201314.","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1002\/cac2.12661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:45:25Z","timestamp":1773823525000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1002\/cac2.12661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/cac2.12661"],"URL":"https:\/\/doi.org\/10.1002\/cac2.12661","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"2024-09-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}